Structured Review

Horizon Discovery rat raf 1 selective sirna mixture
Intrathecal <t>Raf-1-selective</t> <t>siRNA</t> pretreatment attenuates sustained morphine-mediated tactile allodynia. For description of the animal groups see . Paw withdrawal thresholds in response to a series of von Frey filaments applied to the plantar surface
Rat Raf 1 Selective Sirna Mixture, supplied by Horizon Discovery, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat raf 1 selective sirna mixture/product/Horizon Discovery
Average 85 stars, based on 1 article reviews
Price from $9.99 to $1999.99
rat raf 1 selective sirna mixture - by Bioz Stars, 2020-07
85/100 stars

Related Products / Commonly Used Together

non-targeting double-stranded rna dsrna construct

Images

1) Product Images from "Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA"

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA

Journal: British Journal of Pharmacology

doi: 10.1111/j.1476-5381.2010.00869.x

Intrathecal Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated tactile allodynia. For description of the animal groups see . Paw withdrawal thresholds in response to a series of von Frey filaments applied to the plantar surface
Figure Legend Snippet: Intrathecal Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated tactile allodynia. For description of the animal groups see . Paw withdrawal thresholds in response to a series of von Frey filaments applied to the plantar surface

Techniques Used:

Intrathecal (i.th) Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated antinociceptive tolerance. The groups of animals have been described in detail in . After sustained morphine (or saline) treatment, on day 6 the animals
Figure Legend Snippet: Intrathecal (i.th) Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated antinociceptive tolerance. The groups of animals have been described in detail in . After sustained morphine (or saline) treatment, on day 6 the animals

Techniques Used:

Intrathecal (i.th) Raf-1-selective siRNA treatment attenuates sustained morphine-mediated augmentation of calcitonin gene-related peptide (CGRP) immunoreactivity in the lumbar spinal cord of rats. Male Sprague-Dawley rats received i.th vehicle (A, B)
Figure Legend Snippet: Intrathecal (i.th) Raf-1-selective siRNA treatment attenuates sustained morphine-mediated augmentation of calcitonin gene-related peptide (CGRP) immunoreactivity in the lumbar spinal cord of rats. Male Sprague-Dawley rats received i.th vehicle (A, B)

Techniques Used:

Intrathecal Raf-1-selective siRNA treatment attenuates sustained morphine-mediated thermal hyperalgesia. The groups of rats included in the study were explained in . Paw withdrawal latencies in response to radiant heat applied to the plantar surface
Figure Legend Snippet: Intrathecal Raf-1-selective siRNA treatment attenuates sustained morphine-mediated thermal hyperalgesia. The groups of rats included in the study were explained in . Paw withdrawal latencies in response to radiant heat applied to the plantar surface

Techniques Used:

Intrathecal Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated augmentation of calcitonin gene-related peptide (CGRP) levels in lumbar spinal cord homogenates of rats. Male Sprague-Dawley rats were subcutaneously implanted with
Figure Legend Snippet: Intrathecal Raf-1-selective siRNA pretreatment attenuates sustained morphine-mediated augmentation of calcitonin gene-related peptide (CGRP) levels in lumbar spinal cord homogenates of rats. Male Sprague-Dawley rats were subcutaneously implanted with

Techniques Used:

(A) Intrathecal Raf-1-selective siRNA pretreatment reduces Raf-1 protein levels in rat lumbar spinal cord homogenates. Male Sprague-Dawley rats received intrathecal (i.th) injections of transfection reagent (lanes 1–2), 2 µg per 10 µL
Figure Legend Snippet: (A) Intrathecal Raf-1-selective siRNA pretreatment reduces Raf-1 protein levels in rat lumbar spinal cord homogenates. Male Sprague-Dawley rats received intrathecal (i.th) injections of transfection reagent (lanes 1–2), 2 µg per 10 µL

Techniques Used: Transfection

Related Articles

Concentration Assay:

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: .. The rat Raf-1-selective siRNA mixture (Smart pool Dharmacon Inc., Chicago, IL, USA # L-087699-00) and the control, non-targeting double-stranded RNA (dsRNA) construct (Dharmacon Inc., Chicago, IL, USA #D-001810-01-20) were reconstituted in double distilled RNAse-free water to a stock concentration of 100 µM and stored in aliquots at −80°C. .. On the first day of the experiment aliquots of the dsRNA (Raf-1 siRNA or non-targeting dsRNA) stock solutions were mixed (1:5 v/v) with a transfection reagent (i-Fect; Neuromics, Edina, MN, USA) to achieve a final concentration of 2 µg per 10 µL and were administered to the appropriate rat groups through the i.th catheters, once daily for 3 days, as described by ).

Construct:

Article Title: Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA
Article Snippet: .. The rat Raf-1-selective siRNA mixture (Smart pool Dharmacon Inc., Chicago, IL, USA # L-087699-00) and the control, non-targeting double-stranded RNA (dsRNA) construct (Dharmacon Inc., Chicago, IL, USA #D-001810-01-20) were reconstituted in double distilled RNAse-free water to a stock concentration of 100 µM and stored in aliquots at −80°C. .. On the first day of the experiment aliquots of the dsRNA (Raf-1 siRNA or non-targeting dsRNA) stock solutions were mixed (1:5 v/v) with a transfection reagent (i-Fect; Neuromics, Edina, MN, USA) to achieve a final concentration of 2 µg per 10 µL and were administered to the appropriate rat groups through the i.th catheters, once daily for 3 days, as described by ).